DiaMedica Therapeutics Inc - Asset Resilience Ratio
DiaMedica Therapeutics Inc (DMAC) has an Asset Resilience Ratio of 87.53% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See DiaMedica Therapeutics Inc (DMAC) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2010–2025)
This chart shows how DiaMedica Therapeutics Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see DiaMedica Therapeutics Inc (DMAC) total assets.
Liquid Assets Composition Over Time
This chart breaks down DiaMedica Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore DMAC long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $46.46 Million | 87.53% |
| Total Liquid Assets | $46.46 Million | 87.53% |
Asset Resilience Insights
- Very High Liquidity: DiaMedica Therapeutics Inc maintains exceptional liquid asset reserves at 87.53% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
DiaMedica Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare DiaMedica Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for DiaMedica Therapeutics Inc (2010–2025)
The table below shows the annual Asset Resilience Ratio data for DiaMedica Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 72.09% | $44.24 Million | $61.37 Million | -16.64pp |
| 2024-12-31 | 88.73% | $41.12 Million | $46.34 Million | -0.55pp |
| 2023-12-31 | 89.28% | $48.35 Million | $54.16 Million | +5.62pp |
| 2022-12-31 | 83.66% | $28.77 Million | $34.40 Million | -5.05pp |
| 2021-12-31 | 88.70% | $40.41 Million | $45.55 Million | +17.17pp |
| 2020-12-31 | 71.54% | $20.10 Million | $28.09 Million | +27.41pp |
| 2019-12-31 | 44.13% | $4.00 Million | $9.05 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $18.34 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $1.80 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $1.87 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $2.91 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $3.85 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $6.33 Million | -- |
| 2010-12-31 | 0.00% | $0.00 | $9.08 Million | -- |
About DiaMedica Therapeutics Inc
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal… Read more